<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243358</url>
  </required_header>
  <id_info>
    <org_study_id>HFHS 13-03</org_study_id>
    <nct_id>NCT02243358</nct_id>
  </id_info>
  <brief_title>Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer</brief_title>
  <official_title>A Neoadjuvant Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy&#xD;
      incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in&#xD;
      combination with chemo-radiation with gemcitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate frequency of achieving complete resection ( RO resection&#xD;
      )in patients with resectable and borderline resectable pancreatic cancer treated with a&#xD;
      neoadjuvant regimen of FOLFOX followed by radiation therapy (RT) concurrent with gemcitabine&#xD;
      chemotherapy at standard dosing.&#xD;
&#xD;
      Secondary objectives are to determine overall survival and progression-free survival as a&#xD;
      function of time from study enrollment and to evaluate tolerability and toxicity of protocol&#xD;
      treatment.&#xD;
&#xD;
      Eligible patients with resectable and borderline resectable pancreatic cancer will be accrued&#xD;
      onto protocol therapy, which would include a neo-adjuvant phase followed by surgical&#xD;
      resection. A cycle of FOLFOX treatment is 14 days. 2 cycles are intended prior to combined&#xD;
      modality treatment. Combined modality treatment will begin 2 weeks (plus or minus 2 days)&#xD;
      after the last FOLFOX administration. (Gemcitabine 1000mg/mÂ² will be infused over 30 minutes&#xD;
      on days 1, 8, 22, and 29 during the 5-week course of radiation treatment. The surgical&#xD;
      procedure performed will be that required for a complete resection, and this will be based on&#xD;
      the discretion of the operating surgeon. Patients will be followed for 1 year after&#xD;
      completion of neoadjuvant therapy or until removal or termination from study, or until death,&#xD;
      whichever occurs first. Patients will be seen in follow-up ever 3+/- 1 months for 1 year from&#xD;
      completion of protocol therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Tumor Response</measure>
    <time_frame>6 weeks</time_frame>
    <description>Diagnostic imaging and RECIST criteria will be used to evaluate and record response of the primary tumor</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pancreas Neoplasm Malignant Resectable</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folfox6</intervention_name>
    <other_name>5 Fluoropyrymidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreaticoduodenectomy with retroperitoneal lymphadenectomy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed pancreatic adenocarcinoma&#xD;
             of the pancreatic head or body&#xD;
&#xD;
          -  Patients must have radiographically-confirmed surgically resectable or borderline&#xD;
             resectable disease at study entry staged at T1-3, NO-1 and MO&#xD;
&#xD;
          -  Age &gt;/= 18years&#xD;
&#xD;
          -  Life expectancy of greater than 6 months in the opinion of the investigator, excluding&#xD;
             theh pancreatic cancer&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;/= 1&#xD;
&#xD;
          -  Required laboratory data (see protocol)&#xD;
&#xD;
          -  Disease assessment by CT scan within 4 weeks of study entry&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agent&#xD;
&#xD;
          -  Patients with metastatic disease are excluded from this clinical trial&#xD;
&#xD;
          -  History of allergic reactions attributed to Fluorouracil (5FU), oxaliplatin and&#xD;
             gemcitabine&#xD;
&#xD;
          -  No prior chemotherapy or radiation therapy for pancreatic cancer (previous&#xD;
             chemotherapy or radiation therapy for other malignancies is permitted)&#xD;
&#xD;
          -  Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia,&#xD;
             hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the&#xD;
             institution, despite adequate electrolyte supplementation are excluded from this&#xD;
             study.&#xD;
&#xD;
          -  Uncontrolled serious intercurrent illness including, but not limited to, ongoing or&#xD;
             serious active infection requiring IV antibiotics for over 30 days, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than&#xD;
             chronic, stable atrial fibrillation, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          -  Pregnant or breastfeeding women are excluded from this study.&#xD;
&#xD;
          -  Known HIV-positive patients are ineligible&#xD;
&#xD;
          -  Patients with unresectable disease are excluded form the protocol (see Appendix B for&#xD;
             National Comprehensive cancer Network [NCCN] criteria for determining resectability&#xD;
             status). Surgical resectability must be confirmed by a surgeon experienced in&#xD;
             pancreatic surgery.&#xD;
&#xD;
          -  Patients with pancreatic tail lesions will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gazala Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiffany Pearce, BS</last_name>
    <phone>313-916-1784</phone>
    <email>tpearce1@hfhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Carabio, BS</last_name>
    <phone>313-916-1827</phone>
    <email>jcarabi1@hfhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Pearce, BS</last_name>
      <phone>313-916-1784</phone>
      <email>tpearce1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Carabio, BS</last_name>
      <phone>313-916-1827</phone>
      <email>jcarabi1@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Gazala Kahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 4, 2014</study_first_submitted>
  <study_first_submitted_qc>September 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2014</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Gazala Khan, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Pancreatic, cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Through publication in peer reviewed journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

